Title : Tongue Cancer Patients
Can be Distinguished from Healthy Controls by Specific
N-Glycopeptides Found in Serum
Abstract :
- There are no blood biomarkers to detect early-stage oral cavity squamous cell carcinoma (OSCC) prior to clinical signs
- Most OSCC incidence is associated with significant morbidity and poor survival
- The authors aimed to use mass-spectrometry (MS) technology to find specific N-glycope N-glycopeptides lly serving as serum biomarkers for preclinical OSCC screening
- Serum samples from 14 patients treated for OSCC (stage I or stage IV) with 12 age- and sex-matched controls are collected
- Quantitative label-free N-glycoproteomics is performed, with MS/MS analysis of the statistically significantly different N-glycopeptides
- Combined with N-glycopeptides rch using web-based software (GlycopeptideID), MS/MS provided detaile GlycopeptideID de information, including g N-glycopeptide ite, glycan com position, and proposed structures
- Thirty-eight tryptic N-glycopeptides are identified, having N-glycopeptides cosylation sites representing 14 glycoproteins
- OS sites tients, including glycoproteins rs, can be differentiated from healthy controls based on the expression levels of these glycoforms
- N-glycopeptides of IgG1 , IgG4 , haptoglo N-glycopeptides errin have stati haptoglobin gnific transferrin nt abundances between cases and controls
- The authors are the first to suggest specific N-glycopeptides to serve as potential serum biomarkers to detect preclinica N-glycopeptides nts
- structures. Thirty-eight These N-glycopeptides are the lead candidates for validation as future diagnostic N-glycopeptides OSCC as early as stage I